Invasiveness of Hepatocellular Carcinoma Cell Lines: Contribution of Membrane-Type 1 Matrix Metalloproteinase

Neoplasia

Volumn 1, Issue 5, 1999, Pages 424-430

  Murakami, Koji ^a,b   Sakukawa, Rieko ^a   Ikeda, Takashi ^a   Matsuura, Tomokazu ^c   Hasumura, Satoshi ^c   Nagamori, Seishi ^c   Yamada, Yuji ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; HGF; Intrahepatic metastasis; Invasion; MT1 MMP

Indexed keywords

COLLAGEN; GELATINASE A; LAMININ; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; MMP14 PROTEIN, MOUSE; PROTEINASE INHIBITOR; PROTEOGLYCAN; RECOMBINANT PROTEIN; SCATTER FACTOR; UROKINASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER INVASION; CANCER TRANSPLANTATION; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; NUDE MOUSE; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LAMININ; LIVER; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; ORGAN SIZE; PROTEASE INHIBITORS; PROTEOGLYCANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033222965     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900046     Document Type: Article

References (42)

1. Ryu M, Shimamura Y, Kinoshita T, Konishi M, Kawano N, Iwasaki M, Furuse J, Yoshino M, Moriyama N, and Sugita M (1997). Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol 27, 251-257.
2. Tani M, Edamoto Y, Kawai S, Kobori O, Hayashi S, and Hanada K (1997). Results of 90 consecutive hepatectomies for hepatocellular carcinoma: a multivariate analysis of survival. Semin Oncol 24, S6-1-S6-6.
3. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, and Sassa T (1997). Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25, 87-92.
4. Mitsunobu M, Toyosaka A, Oriyama T, Okamoto E, and Nakao N (1996). Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis 14, 520-529.
5. The Liver Cancer Study Group of Japan (1994). Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74, 2772-2780.
6. Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, Niwano M, Ishigami S, Fukumoto M, Seiki M, Sato H, and Imamura M (1998). Membrane-type matrix metalloproteinase-1 (MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 28, 231-239.
7. Wun TC (1988). Plasminogen activation: biochemistry, physiology, and therapeutics. Crit Rev Biotechnol 8, 131-148.
8. Keski-Oja J, Koli K, Lohi J, and Laiho M (1991). Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin Thromb Hemostasis 17, 231-239.
9. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, and Saisho H (1996). Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24, 1058-1062.
10. Yamamoto H, Itoh F, Adachi Y, Sakamoto H, Adachi M, Hinoda Y, and Imai K (1997). Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 112, 1290-1296.
11. Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M, and Imamura M (1996). Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24, 316-322.
12. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, and Barlati S (1998). Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58, 2234-2239.
13. Murakami K, Matsuura T, Sano M, Hashimoto A, Yonekura K, Sakukawa R, Yamada Y, and Saiki I (1998). 4-[3,5-Bis(trimethylsilyl)-benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor bearing animals. Clin Exp Metastasis 16, 633-643.
14. Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, and LaRochelle WJ (1996). Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 7, 1513-1523.
15. Tajima H, Matsumoto K, and Nakamura T (1992). Regulation of cell growth and motility by hepatocyte growth factor and receptor exptession in various cell species. Exp Cell Res 202, 423-431.
16. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, and Comoglio PM (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119, 629-641.
17. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, and Aranson SA (1991). Identification of the hepatocyte growth factor receptor as the c-MET proto-oncogene product. Science 251, 802-804.
18. Uchiyama A, Essner R, Doi F, Nguyen T, Ramming KP, Nakamura T, Morton DL, and Hoon DS (1996). Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. J Cell Biochem 62, 443-453.
19. Kaji M, Yonemura Y, Harada S, Liu X, Terada I, and Yamamoto H (1996). Participation of c-MET in the progression of human gastric cancers: anti-c-MET oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 3, 393-404.
20. Nakamura T, Matsumoto K, Kiritoshi A, Tano Y, and Nakamura T (1997). Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57, 3305-3313.
21. Li H, Shimura H, Aoki Y, Date K, Matsumoto K, Nakamura T, and Tanaka M (1998). Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clin Exp Metastasis 16, 74-82.
22. Nishimura K, Kitamura M, Takada S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K, and Okuyama A (1998). Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 5, 276-281.
23. Kamiyama T, Une Y, Uchino J, and Hamada J (1998). Hepatocyte growth factor enhances the invasion activity of human hepatocellular carcinoma cell lines. Int J Oncol 12, 655-659.
24. Arakaki N, Kawakami S, Nakamura O, Ohnishi T, Miyazaki H, Ishii T, Tsubouchi H, and Daikuhara Y (1995). Evidence for the presence of an inactive precursor of human hepatocyte growth factor in plasma and sera of patients with liver diseases. Hepatology 22, 1728-1734.
25. Sakon M, Monden M, Gotoh M, Umeshita K, Mori T, Tsubouchi H, Kanai T, Umeshima K, and Mori T (1992). Hepatocyte growth factor concentrations after the liver resection. Lancet 339, 818.
26. Ueki J, Fujimoto J, Suzuki T, Yamamoto H, and Okamoto E (1997). Expression of hepatocyte growth factor and its receptor c-MET protooncogene in hepatocellular carcinoma. Hepatology 25, 862-866.
27. Fujise K, Nagamori S, Hasumura S, Homma S, Sujino H, Matsuura T, Shimizu K, Niiya M, Kameda H, Fujita K, and Ohno T (1990). Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Hepatogastroenterology 37, 457-460.
28. Yamamoto M, Mohannam S, Sawaya R, Fuller GN, Seiki M, Sato H, Gokaslan ZL, Liotta LA, Nicolson GL, and Rao JS (1996). Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 56, 384-392.
29. Onisto M, Garbisa S, Caenazzo C, Freda MP, Di Francesco C, Nitti D, Liotta LA, and Stetler-Stevenson WG (1995). Reverse transcription-polymerase chain reaction phenotyping of metalloproteinases and inhibitors involved in tumor matrix invasion. Diagn Mol Pathol 2, 74-80.
30. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, and Blasi F (1995). The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res 13, 2759-2771.
31. Min HY, Semnani R, Mizukami IF, Watt K, Todd RF, and Liu DY (1992). cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol 148, 3636-3642.
32. Saito K, Ata N, Miyashiro H, Hattori M, and Saiki I (1997). A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors. Biol Pharm Bull 20, 345-348.
33. Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, and Okada Y (1998). Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem 41, 1209-1217.
34. Steward WP (1999). Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 43 Suppl, S56-60.
35. Ata N, Oku T, Hattori M, Fujii H, Nakajima M, and Saiki I (1996). Inhibition by galloylglucose (GG6-10) of tumor invasion through extracellular matrix and gelatinase-mediated degradation of type IV collagens by metastatic tumor cells. Oncol Res 12, 503-511.
36. Hochberg Y, and Tamhane AC (1987). Multivariate t-distribution. In: Multiple Comparison Procedures, Volume 12. New York: John Wiley and Sons, 374-375.
37. Mignati P, and Rifkin DB (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73, 161-195.
38. Stetler-Stevenson WG, Aznavoorian S, and Liotta LA (1993). Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9, 541-573.
39. Chambers AF, and Matristan LM (1997). Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89, 1260-1270.
40. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, and Seiki M (1994). A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370, 61-65.
41. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, and Okada Y (1997). Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272, 2446-2451.
42. Andreasen PA, Kjoller L, Christensen L, and Duffy MJ (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72, 1-22.